Benefits
Cognitive function in older adults
Cognigrape® at 250 mg/day produces measurable improvements across multiple cognitive domains in healthy older adults: attention, language, immediate memory, and delayed memory all improve significantly. Visuospatial abilities don't change. Effect is replicated across multiple trials at the same dose. Reasonable consideration for older adults concerned about subjective cognitive decline; not validated as a nootropic for healthy younger adults.
Lower depression-inventory scores in older adults
In one small manufacturer-affiliated trial (n=111, healthy older adults, 250 mg/day for 12 weeks), Beck Depression Inventory scores fell about 16% versus placebo. This is a single secondary endpoint from one trial in people who did not have clinical depression, and the 2024 follow-up did not re-measure it. It has not been tested as a treatment for major depression and should not be used as one.
Anxiety-scale scores in older adults
In the same single manufacturer-affiliated trial, Hamilton Anxiety Rating Scale scores fell about 25% versus baseline, but the placebo comparison reached only p<0.05, the weakest result in that trial. The 2024 follow-up did not re-measure anxiety. This is one secondary endpoint in older adults without an anxiety disorder, not a demonstrated anxiolytic, and it has not been tested against or as a substitute for anxiety medication.
Memory specifically — immediate and delayed
Cognigrape®'s strongest cognitive signal is on memory — both immediate recall and delayed recall show significant improvement. Memory is the cognitive domain most concerning in age-related decline, so this is the most clinically relevant effect. Effect emerges within 2 weeks of starting and continues building through 12 weeks. Practical takeaway: the cognitive benefit isn't generalized 'mental clarity' marketing — it's specifically memory.
Effect can appear within 2 weeks
Unusual for a polyphenol supplement — Cognigrape® shows measurable cognitive effects as early as 14 days, not just at the typical 8-12 week mark seen with most botanicals. Continued improvement through 12 weeks. Useful expectation-setting: if no subjective improvement by 4-6 weeks, the supplement probably isn't producing meaningful benefit for that individual. Don't waste 6 months of supplementation hoping for delayed onset.
Branded extract — generic grape extracts won't substitute
Cognigrape® is a specific Sicilian grape variety standardized for both anthocyanins and proanthocyanidins — the clinical evidence is for this exact branded extract. Generic 'grape seed extract' or 'grape skin extract' products have different polyphenol profiles and have not been tested in the same trials. If you want the documented cognitive effects, use Cognigrape® specifically — don't substitute generic grape extracts based on the assumption they're equivalent.
Mechanism of action
Anthocyanin BBB penetration (CNS effects)
Anthocyanins from Cognigrape® cross BBB and exert direct CNS effects: neuroprotection, BDNF modulation, anti-inflammatory effects in microglia, antioxidant defense enhancement. Mechanism for cognitive enhancement and possibly mood effects.
Proanthocyanidin vascular effects
Proanthocyanidins improve endothelial function via NO production, reduce oxidative damage to vascular endothelium. Improved cerebral perfusion contributes to cognitive benefits. Mechanism complementary to direct CNS effects.
Resveratrol-related mechanisms
Sicilian grape extract contains resveratrol — SIRT1 activation, mitochondrial biogenesis support, neuroprotective effects. Mechanism for longevity-related cognitive benefits. Lower concentration than dedicated resveratrol supplements but contributes to overall polyphenol profile.
Antioxidant via direct ROS scavenging
Comprehensive polyphenol antioxidant profile — direct scavenging of hydroxyl, peroxyl, superoxide radicals. Particularly effective against oxidative damage in CNS where chronic inflammation contributes to age-related cognitive decline.
Anti-inflammatory NF-κB pathway modulation
Polyphenols suppress NF-κB activation and pro-inflammatory cytokine expression. Mechanism for chronic inflammation reduction. Relevant to systemic + neuroinflammatory cognitive aging.
BDNF and synaptic plasticity support
Polyphenol metabolites in CNS modulate BDNF expression and synaptic plasticity markers. Mechanism for cognitive enhancement, learning, memory. Distinct from acute receptor modulation.
Mood/depression effects via combined mechanisms
Combined cognitive enhancement (reducing cognitive-related anxiety/depression) + direct polyphenol effects on mood-related neurotransmitter systems + anti-inflammatory effects (depression has an inflammatory component). Mechanism for the documented BDI/HARS reductions.
Clinical trials
Randomized double-blind placebo-controlled clinical trial (Calapai G, Bonina F, Bonina A, Rizza L, Mannucci C, Arcoraci V et al. 2017, Front Pharmacol 8:776, doi:10.3389/fphar.2017.00776).
111 healthy older adults randomly divided into two groups: Cognigrape® 250 mg/day (n≈55) vs placebo (n≈56) for 12 weeks. Cognitive function and neuropsychological status assessed via MMSE, Beck Depression Inventory (BDI), Hamilton Anxiety Rating Scale (HARS), and RBANS evaluations.
MMSE significantly improved vs baseline (p<0.0001) and vs placebo (r=0.59, 95% CI 0.11-1.22, p<0.0001). BDI reduced 15.8% (p<0.0001 vs baseline and placebo). HARS reduced 24.9% (p<0.0001 vs baseline; p<0.05 vs placebo). RBANS total score significantly improved (r=0.55, 95% CI 0.48-6.07, p<0.0001). RBANS domains: attention (p<0.001), language (p<0.05), immediate memory (p<0.0001), delayed memory (p<0.0001). Visuospatial/constructional abilities not modified. NO adverse effects detected. Foundational pivotal clinical trial.
Randomized double-blind placebo-controlled trial (Amone F, Spina A, Perri A, Lofaro D, Zaccaria V, Insolia V, Lirangi C, Puoci F, Nobile V. 2024, Foods 13(18):2999, doi:10.3390/foods13182999, PMID 39335927). Manufacturer-affiliated: a Bionap employee is among the authors.
96 healthy older adults randomized to Cognigrape® 250 mg/day vs placebo for 84 days. Multiple cognitive assessments at multiple time points.
Significant improvements across multiple cognitive domains: immediate memory, delayed memory, visuospatial abilities, language, attention. Improvements occurring within 14 days, continuing to improve after 84 days. Confirms findings with extended timeline characterization. Demonstrates both short-term acute and long-term sustained benefits.